H.R. 4207 · 114th Congress
Medicare Fair Drug Pricing Act of 2015
Key: what the circles and colors mean
Each circle is a bill. The ring fills as it moves through Congress:
Under the number: the Yea · Nay count of its final (or latest) recorded vote. On a member's page, the small badge is how that member voted: Y Yea / Aye, N Nay / No, P Present, – Not voting.
Gold and violet are only for Yea and Nay; they never mean a party. A member's party is the letter on their photo.
Never voted on. It didn't reach a floor vote before the 114th Congress ended, so it expired. A bill has to be introduced again to be considered in a new Congress.
D
SchakowskySponsor10 cosponsors · 10 D
D
Cummings
RD
D
DeLauro
LD
D
Doggett
BL
D
Lee
JM
D
McDermott
MP
D
Pocan
PW
D
Welch
MH
D
Honda
BT
D
Thompson
EB
D
Blumenauer7 signed on when it was introduced; the rest joined later. Cosponsors who withdrew aren't shown.
This bill amends title XVIII (Medicare) of the Social Security Act to require the Centers for Medicare & Medicaid Services (CMS) to negotiate with drug manufacturers in determining the price that may be charged for prescription drugs under the Medicare prescription drug benefit.
What it does: CRS summary · Introduced in House · Dec 9, 2015
Medicare Fair Drug Pricing Act of 2015
This bill amends title XVIII (Medicare) of the Social Security Act to require the Centers for Medicare & Medicaid Services (CMS) to negotiate with drug manufacturers in determining the price that may be charged for prescription drugs under the Medicare prescription drug benefit.
Under current law, CMS may not interfere with negotiations between drug manufacturers and prescription drug plan (PDP) sponsors. The bill creates an exception to this prohibition with respect to specified drugs that: (1) are single-source or biological, (2) are not both manufactured by more than two drug manufacturers and manufactured by at least one manufacturer as a generic drug, and (3) meet other specified requirements. CMS must promulgate regulations regarding the identification of such drugs.
With respect to these drugs, CMS shall negotiate the price that may be charged to PDP sponsors and Medicare Advantage (MA) organizations for Medicare and MA enrollees. The bill establishes processes for negotiation and price determination in the initial plan year and subsequent plan years.
A manufacturer must participate in the negotiation process as a condition of coverage under the Medicare prescription drug benefit.
Written by the nonpartisan Congressional Research Service. All summary versions on Congress.gov
About this bill and sources
Official title: Medicare Fair Drug Pricing Act of 2015
Latest action (Dec 11, 2015): Referred to the Subcommittee on Health.
Policy area: Health · Origin: House · Introduced: Dec 9, 2015
Official page on Congress.gov · Bill text (GovInfo) · Status record (XML)
No recorded floor vote found.